Vitae's Vagueness On Psoriasis Program Spooks Investors
Decision to end enrollment prematurely of Phase IIa proof-of-concept study apparently has led investors to assume safety issues for the first-in-class ROR gamma T inhibitor.
Decision to end enrollment prematurely of Phase IIa proof-of-concept study apparently has led investors to assume safety issues for the first-in-class ROR gamma T inhibitor.